PARIS – Nanobiotix SA has submitted its lead product NBTXR3 – the first generation of nanoparticle radio-enhancers targeting human cells – for first market approval in Europe. This nanotechnology is intended to resolve radiation therapy's biggest drawback: the destruction of healthy tissue and subsequent deleterious side effects when high X-ray doses are necessary.

Pessac, France-based Poietis SAS is developing a platform of laser-assisted 3-D bioprinting for the cosmetics and pharmaceuticals industries as well as regenerative medicine centers. The French startup is preparing to target the European, North American and Japanese markets with its print-manufactured living tissues.